Both EZH2 and NF-kB contribute to aggressive breast cancer, yet whether the two oncogenic factors have functional crosstalk in breast cancer is unknown. Here, we uncover an unexpected role of EZH2 in conferring the constitutive activation of NF-kB target gene expression in ER-negative basal-like breast cancer cells. This function of EZH2 is independent of its histone methyltransferase activity but requires the physical interaction with RelA/RelB to promote the expression of NF-kB targets. Intriguingly, EZH2 acts oppositely in ER-positive luminal-like breast cancer cells and represses NF-kB target gene expression by interacting with ER and directing repressive histone methylation on their promoters. Thus, EZH2 functions as a double-facet molecule in breast cancers, either as a transcriptional activator or repressor of NF-kB targets, depending on the cellular context. These findings reveal an additional mechanism by which EZH2 promotes breast cancer progression and underscore the need for developing context-specific strategy for therapeutic targeting of EZH2 in breast cancers.
INTRODUCTION
Breast cancer can be categorized into two subtypes, basal-like and luminal-like breast carcinoma, with the former being the more aggressive and metastatic form of breast cancer. Luminallike breast carcinomas that generally harbor the expression of estrogen receptor (ER), progesterone receptor (PR), and human epithelial growth factor receptor 2 (HER2) are responsive to antihormone treatment. In contrast, basal-like breast carcinomas are often triple negative (ER-, PR-, HER2-) and are resistant to targeted therapy. Understanding the molecular pathways associated with basal-like breast cancers is thus required for developing more effective approaches for breast cancer treatment.
Polycomb histone methyltransferase enhancer of zeste homolog 2 (EZH2) is overexpressed in multiple human malignancies and has roles in regulating a variety of cellular processes, including cell proliferation, apoptosis, invasion, and self-renewal . EZH2 is a crucial component of polycomb repressor complex 2 (PRC2), and its oncogenic function is thought mainly to be mediated through its gene silencing activity. A number of putative tumor suppressors, including INK4A/ARF (Agherbi et al., 2009; Bracken et al., 2007) , p57 , RUNX3 (Fujii et al., 2008) , Bim (Wu et al., 2010) , and FBXO32 (Tan et al., 2007; Wu et al., 2010) , have been found to be EZH2 targets. In breast cancers, higher EZH2 expression is known to be more associated with aggressive basal-like subtype and poor metastasis-free survival (Kleer et al., 2003; Puppe et al., 2009 ). It has also been shown recently that EZH2 plays a role in supporting self-renewal of breast tumor initiating cells . These findings have highlighted an important role of EZH2 in aggressive breast cancers; yet, the mechanism(s) governing the oncogenic role of EZH2 in such a disease remains to be elucidated.
Another oncogenic pathway known to be associated with ERnegative or basal-like breast cancer is nuclear factor-kappaB (NF-kB) signaling (Biswas et al., 2001; Freund et al., 2004; Pratt et al., 2003) . In breast cancer cells, ER has been known for long to repress NF-kB-dependent transcription (Gionet et al., 2009) , though the mechanism for this inhibition has never been fully elucidated. In addition, constitutive activation of NF-kB targets such as IL6 and IL8 has been found in ER-negative basal-like breast cancer cells (Freund et al., 2003; Sansone et al., 2007) . In addition to RelA and/or c-Rel mediated activation of canonical pathway of NF-kB in human cancer, aberrant activation of noncanonical NF-kB pathway, mediated by RelB, has also been reported in a number of human cancers, including ER-negative breast cancer (dos Santos et al., 2008; Lee et al., 2009; Xu et al., 2009 ). In particular, ER represses RelB expression in ER-positive cancer cells . Furthermore, constitutive activation of RelB has been shown to be associated with ER-negative basal-like breast cancers and promote their metastasis (Fritz and Radziwill, 2010; Wang et al., 2007) . However, the underlying mechanism leading to the constitutive activation of RelB-associated NF-kB signaling in breast cancer is largely unknown. In the present study, we exploited EZH2-regulated transcriptome in basal-like breast cancer cells and identified an unexpected role of EZH2 in modulating NF-kB signaling activity.
RESULTS

EZH2 Positively Regulates NF-kB-Mediated Gene Network in Aggressive Breast Cancer Cells
To gain mechanistic insights into the role of EZH2 in aggressive breast cancers, we sought to determine EZH2-dependent gene expression in basal-like breast cancer cells. To this end, we depleted EZH2 by small interference RNA (siRNA) in triple-negative MDA-MB-231 cells and performed gene expression analysis with Illumina 24K human BeadArray-V2. Gene expression analysis led to identification of 836 genes that were differentially expressed upon EZH2 depletion (with 2-fold cutoff, p < 0.01), including 391 genes upregulated and 445 genes downregulated, respectively (Table S1 available online). This observation indicates with interest that in addition to the well-known function of EZH2 in gene repression, EZH2 may also have a similar capacity in promoting gene activation, though it could be an indirect effect. Nevertheless, to gain further insights into the latter function of EZH2, we performed Ingenuity Pathway Analysis (IPA) and identified several gene networks that were highly enriched in EZH2-positively regulated gene set ( Figure 1A ). Interestingly, genes enriched in inflammatory response was one such network, displaying a well interconnected regulatory system with NF-kB as a central node ( Figure 1B , left), whose downregulation after EZH2 depletion was further illustrated in a gene expression heat map (Figure 1B, right) . Among these genes are many well-known NF-kB target genes, such as IL6 and IL8, which have been implicated in breast cancer oncogenesis (Benoy et al., 2004; Sansone et al., 2007) .
To further validate and nominate NF-kB target genes that are positively regulated by EZH2, we depleted RelA or RelB in MDA-MB-231 cells and compared the gene expression profile with that in EZH2-depleted cells. We identified 129 and 101 genes that were downregulated after RelA and RelB knockdown (with 2-fold cutoff), respectively, including a common set of 62 genes coregulated by both RelA and RelB ( Figure 1C and Table S2 ). Among RelA-and RelB-regulated genes, 48 were also downregulated after EZH2 knockdown, as illustrated by Venn diagram ( Figure 1C) , showing that a significant set of NF-kB targets (approximately 28%) appeared to be downregulated by EZH2 depletion (p < 0.001). Thus, this unbiased genome-scale analysis reveals an unexpected role of EZH2 in positively modulating NFkB target gene expression in MDA-MB-231 cells.
To verify the effect of EZH2 knockdown on NF-kB activity in basal-like breast cancer cells, we performed NF-kB-specific luciferase reporter assay in MDA-MB-231 and another basallike breast cancer cell line BT549. Similar to RelA or RelB knockdown, EZH2 knockdown in both cell lines clearly reduced the reporter activity of NF-kB ( Figure 1D, top) ; however, it had no effect on RelA or RelB protein expression, excluding the possibility that this change of NF-kB activity might be indirectly caused by affecting RelA or RelB expression ( Figure 1D, bottom) . Notably, the protein expression of RelB was significantly reduced after the depletion of RelA because RelB is a direct target of RelA (Bren et al., 2001) . In accordance with the reduced NF-kB reporter activity after EZH2 depletion, expression levels of NF-kB targets TNF and IL8 were markedly downregulated in MDA-MB-231 and BT549 cells ( Figure 1E ). Furthermore, in addition to the basal activity of NF-kB, we show that TNFa-induced NF-kB activation was also abolished by EZH2 knockdown in MDA-MB-231 and BT549 cells ( Figure 1F ). Collectively, these findings validate a positive role of EZH2 in conferring the NFkB-dependent transcription in aggressive breast cancer cells.
EZH2 Positively Modulates NF-kB Target Gene
Expression Independently of Histone Methyltransferase Activity EZH2 SET domain is required to induce gene silencing by catalyzing H3K27 trimethylation (Shi et al., 2007) . We next asked whether such a catalytic function is required for EZH2 to positively regulate NF-kB-dependent transcription. We first compared the EZH2 and EZH2 SET domain deletion mutant (EZH2 SETD) in their abilities to rescue the downregulation of NF-kB activity in EZH2-depleted cells. In this experiment, we used another siRNA that targets the EZH2 5 0 untranslated region (UTR) and thus is unable to affect the exogenous EZH2. In both MDA-MB-231 and BT549 cells, depletion of the endogenous EZH2 and the associated H3K27me3 by this siRNA were effectively rescued by the ectopic expression of the wild-type EZH2, leading to a marked restoration of NF-kB activity (Figure 2A) . Interestingly, EZH2 SETD, which lacked the methyltransferase activity for H3K27me3, was still able to strongly rescue NF-kB activity after EZH2 knockdown, suggesting a SET domain-independent activity of EZH2 on NF-kB ( Figure 2A) . Notably, ectopic EZH2 SETD depleted the endogenous EZH2 and H3K27me3 and consistently displayed higher levels of protein accumulation compared to the ectopic WT EZH2 (Figure 2B) . Furthermore, in an immortalized human mammary epithelial cell (HMEC) line, retroviral overexpression of EZH2 SETD resulted in a robust induction of NF-kB reporter activity, although the EZH2 WT had only a modest effect, probably due to insufficient overexpression of EZH2 ( Figure 2C ). This change of NF-kB activity was also consistent with the induction of of NF-kB targets TNF, IL6, and IL8 expression ( Figure 2D ), but not observed on a negative control gene ( Figure S1A ). Collectively, these findings demonstrate that EZH2-mediated activation of NF-kB signaling does not require histone methylation catalytic activity.
EZH2 Forms a Ternary Complex with RelA and RelB in Aggressive Breast Cancer Cells
The above findings raised a possibility that EZH2 may directly modulate NF-kB signaling. To explore this possibility, we began to ask whether EZH2 regulates NF-kB signaling through physical association with RelA or RelB, the two main members of NF-kB. To examine this hypothesis, we performed coimmunoprecipitation (coIP) in MDA-MB-231 with or without the stimulation of TNFa. In each respective immunoprecipitates of RelA, RelB, or EZH2, we were able to detect the other two proteins, which were further enriched upon TNFa-treatment (Figure 3A, left) . Notably, RelA was found to be coimmunoprecipitated with RelB, which is consistent with a previous report (Jacque et al., 2005) . These results indicate that endogenous EZH2 forms a complex with RelB and RelA in MDA-MB-231 cells; yet, while SUZ12, a component of PRC2 (mainly contains EZH2, SUZ12 and EED), was found in EZH2 immunoprecipitates, it was not detected in RelB or RelA immunoprecipitates. This indicates that EZH2 can form two separate protein complexes in MDA-MB-231 cells; one is PRC2, and the other is EZH2/RelB/RelA. Densitometry analysis of western blot showed that approximately 1%-2% of total EZH2 was associated with RelA/RelB and 4%-5% of RelA/RelB interacted with EZH2 ( Figure 3A , right). These data are consistent with the previous gene expression analysis showing that only a portion of NF-kB targets were affected after EZH2 depletion. Given Tables S1 and S2. that EZH2 SETD could also rescue the transcriptional activity of NF-kB, we hypothesized that the association of EZH2 with RelA/ RelB is independent of the SET domain. To test this possibility, we performed coIP in 293T cells transfected with myc-tagged EZH2 WT or EZH2 SETD. We observed that RelB was detected in both EZH2-and EZH2 SETD immunoprecipitates, which was more evident upon TNFa stimulation. Compared with RelB, RelA appeared to be less interactive with EZH2 and their interaction was only evident in EZH2 SETD immunoprecipitates (Figure 3B) , suggesting that EZH2 may preferentially associate with RelB in this experimental condition. To demonstrate a direct interaction between EZH2 and RelA/RelB, we performed in vitro pull-down assay using bacterial expressed recombinant proteins. As shown in Figure 3C , both MBP-RelA or-RelB recombinant fusion proteins could associate with GST-EZH2, indicating a direct interaction between EZH2 and RelA/RelB (Figure 3C) . To further provide evidence that the three components form a ternary complex, we performed in vitro pull-down followed by a sequential immunoprecipitation. We observed that when we subjected the eluates of GST pull-down to RelAspecific immunoprecipitation, RelB was only detected in GST-EZH2 pull-down sample, but not in either the IgG counterpart or GST control pull down ( Figure 3D ). This indicates that the EZH2-interacting RelA simultaneously associates with RelB in the same complex. Crucially, the endogenous RelB is essential for endogenous EZH2-RelA complex formation in MDA-MB-231 cells, in which the interaction between EZH2 and RelA became nearly undetectable upon RelB knockdown ( Figure 3E ). Taken all together, these biochemical data indicate the formation of a ternary complex between endogenous EZH2, RelB and RelA in MDA-MB-231 cells, thus providing a potential mechanistic link to constitutive activation of NF-kB in aggressive breast cancers.
EZH2 and RelA/RelB Coregulate a Subset of NF-kB Targets by Interdependent Promoter Occupancy
Given that EZH2 may regulate NF-kB target genes through complexing with RelA and RelB, which have known oncogenic roles in aggressive breast cancers (Helbig et al., 2003; Wang et al., 2007) , we next sought to identify EZH2/RelA/RelB-coregulated NF-kB targets that might be associated with aggressive breast cancer. To differentiate NF-kB targets that are regulated by EZH2/RelA/RelB from those that are only regulated by RelA, we further compared the gene expression profiles of TNFatreated and untreated cells upon individual knockdown of EZH2, RelA, or RelB. TNFa treatment activates RelA more rapidly and more robustly than RelB and thus allows distinguishing RelA and RelB target genes (Derudder et al., 2003) . Gene clustering analysis identified two clusters of EZH2-regulated NF-kB targets that were differentially affected by RelA or RelB knockdown. Although all the EZH2-regulated NF-kB targets were sensitive to RelA knockdown as anticipated, one cluster (n = 46) also showed a strict dependency on RelB upon TNFa treatment, whereas the second cluster (n = 6) remained to be induced by TNFa, albeit RelB or EZH2 knockdown ( Figure 4A ). This observation was further confirmed by qRT-PCR analysis of representative genes from each cluster ( Figure 4B ). The dependence of IL6 or TNF expression on RelB was further verified by ectopic expression of RelB in MDA-MB-231 cells. qRT-PCR analysis showed that IL6 or TNF expression was highly responsive to ectopic RelB, which rescued the inhibition by EZH2 knockdown in vector control cells ( Figure 4C ). In contrast, IL8 and BIRC3 from the second cluster were neither responsive to ectopic RelB, nor altered after EZH2 knockdown upon TNFa treatment. Taken together, these findings support that EZH2-regulated NF-kB targets such as IL6 and TNF from the first cluster are RelB dependent, while the second cluster of NF-kB target genes such as IL8 and BIRC3 were not dependent on RelB. The effect of EZH2 or RelB knockdown on the basal expression of IL8 and BIRC3 may result from an indirect effect of reduced expression of endogenous TNF, which may further lead to attenuated autocrine feedback activation of NF-kB targets.
To understand the mechanisms by which EZH2 selectively cooperates with RelA and RelB toward NF-kB target gene regulation, we next analyzed the promoter binding of EZH2, RelB or RelA by chromatin immunoprecipitation (ChIP) in TNFa-treated MDA-MB-231 cells by using a panel of PCR primer pairs that spanned the gene promoters of IL6, TNF, IL8, and BIRC3. Significantly, all three proteins were found to be highly enriched in both IL6 and TNF promoters with binding peaks around the 1000-500 bp upstream of the transcription start sites, but not in a negative control gene promoter ( Figure 4D and Figure S1B ). However, despite a high EZH2 enrichment, no corresponding H3K27me3 enrichment was detected on IL6 and TNF promoter ( Figure 4D ), further supporting a histone methylation-independent activity of EZH2. In contrast, IL8 and BIRC3 promoters only displayed high RelA binding, but not EZH2 and RelB binding ( Figure 4D ). Importantly, TNFa-induced recruitments of RelA and RelB to IL6 and TNF promoters were markedly reduced by EZH2 knockdown ( Figure 4E) . Similarly, knockdown of RelB also decreased the recruitment of EZH2 and RelA ( Figure 4E) . No difference was observed on the negative control gene promoter ( Figure S1C ). These results indicate that recruitments of EZH2, RelA, and RelB to IL6 and TNF gene promoters are IL6  TNF  IL8  BIRC3  IL6  TNF  IL8  BIRC3  IL6  TNF  IL8 interdependent. In contrast, EZH2 or RelB knockdown had no effect on RelA binding to IL8 and BIRC3 promoters, further validating their independency on EZH2 and RelB.
To demonstrate the spatial co-occupancy of the EZH2, RelA and RelB, extensive pairwise sequential ChIP was carried out. After the EZH2 first ChIP, both RelA and RelB binding were enriched in EZH2-bound IL6 and TNF promoters, but not in IL8 and BIRC3 promoters ( Figure 4F, left) , indicating that RelA/ RelB were concurrently bound to these promoter with EZH2. Similar results were also obtained in RelA or RelB first ChIP experiments ( Figure 4F , middle and right). We conclude that EZH2, through interacting with RelA and RelB, is required for the establishment of constitutive activation for a set of NF-kB target genes in basal breast cancer cells, providing insights into how EZH2 can act as a transcriptional activator in breast cancers.
NF-kB Target Gene Signature Coregulated by EZH2, RelA, and RelB Discriminates Basal versus Luminal Subtype of Breast Cancers and Is Associated with Poor Disease Outcome
To determine whether EZH2/RelA/RelB coregulated NF-kB target gene set identified in MDA-MB-231 cells are also associated with other basal-like breast cancer cell lines, we interrogated the published gene expression data set generated from 54 breast cancer cell lines, including 26 basal and 25 luminal (and three uncharacterized) (Neve et al., 2006) and performed nonsupervised clustering analysis based on this gene set. Strikingly, the EZH2-and NF-kB-coregulated gene list was able to distinguish basal from luminal type breast cancer cells with high efficiency (90% properly segregated) ( Figure 5A ). We further identified a subset of 12 genes expressed in higher levels in both individual levels and in average in basal cell lines compared to the luminal type (p = 0.0001) ( Figure 5A and 5B, left, and Figure S2A ). This indicates that deregulation of these genes is not just limited to MDA-MB-231 cells, but common to basal-like breast cancer cell lines in general. Notably, genes that were included in this 12 gene set such as IL6, SAA, PTGS2 (encoding Cox2) have been previously shown to be associated with aggressive breast cancers and poor disease outcome (Pierce et al., 2009; Sansone et al., 2007; Zhao et al., 2008) . Importantly, expressions of these genes are positively correlated with the higher expressions of EZH2 and RELB in basal-like breast cancer cells, but reversely correlated with the expression of ER or ER-related genes (GATA3 and FOXA1) ( Figures 5A and 5B, middle and right).
To further establish the clinical significance of this finding, we carried out an expression analysis of these 12 genes using two microarray data sets from Farmer and Netherlands breast cancer cohorts (Bos et al., 2009; Farmer et al., 2005) downloaded from Oncomine. The result showed that in both cohorts the averaged or individual expression of the 12 signature genes were significant higher in basal or ER-negative breast cancer samples as compared with luminal or ER-positive breast tumors ( Figure 5C , left, and Figures S2B and S2C) , which is correlated with the higher expression of EZH2 and RELB in basal-like breast tumor samples, but reversely correlated with ER, FOXA1 and GATA3 in these samples ( Figure 5C, middle and right) . Moreover, Kaplan-Meier survival analysis also showed a prognostic value of this 12 gene set in breast cancer. Specifically, as demonstrated in the Netherlands cohort, when we classified the expression levels of the genes based on the mean value, the breast cancer patients with higher expression of this gene set showed a consistent lower brain-and lung-metastasis-free survival probability in Kaplan-Meier plots with p = 0.0188 and p = 0.0152, respectively ( Figure 5D ). When we further plotted the survival rate of the patients based on quartile expression of the 12 genes, a more significant difference in brain-and lung-metastasis-free survival probability was observed with p = 0.0025 and p = 0.0065, respectively ( Figure 5E ). As a control, NF-kB targets that are not regulated by EZH2 were not found to be associated with brain or lung metastasis-free survival ( Figure S2D ). Taken together, these results indicated that the expression levels of the 12 genes correlated inversely with the brain-and lungmetastasis-free survival probability of breast cancer patients thus validated the clinical relevance of EZH2/RelA/RelB-regulated gene set to aggressive breast cancers.
To validate the role of EZH2/RelA/RelB in regulating the invasiveness of breast cancer cells, we performed transwell invasion assay using MDA-MB-231 with EZH2/RelA/RelB individual gene or combination knockdown. We showed that each of the EZH2, RelA, or RelB depletion reduced the invasive capacity of MDA-MB-231 cells, and combined knockdown gave rise to a more profound inhibition ( Figure S3A) . A similar result was also observed when we performed 3D matrigel growth assay (Figure S3B ). This indicates that EZH2, RelA, RelB can regulate the aggressive behaviors of basal breast cancer cells through both overlapped and independent mechanisms.
EZH2 Negatively Regulates NF-kB Target Genes in ER-Positive Luminal-like Breast Cancer Cells
We have previously reported that EZH2 depletion in ER-positive luminal-like MCF-7 cells activates the expression of many inflammatory cytokines, including known NF-kB targets ). This discrepancy between luminal and basal-like breast cancer cell lines such as MDA-MB-231 and BT549 indicates that EZH2 acts differently in regulating NF-kB target gene expression, depending on the cellular context. ER has been known for long to repress NF-kB activity and target gene expression (Nakshatri et al., 1997; Pratt et al., 2003) . In addition, ER has also been reported to repress RelB expression in MCF-7 cells . In agreement with these earlier findings, we found that many NF-kB targets were highly expressed in ER-negative MDA-MB-231 cells but repressed in ER-positive MCF-7 cells, which was inversely correlated with the expression of ER and the two well-known ER cofactors, FOXA1 and GATA3 ( Figure 6A ). Depletion of either EZH2 or ER in MCF7 or another ER-positive T47D cells resulted in marked induction of IL6 and IL8 expression at both basal level and TNFa-treated conditions ( Figure 6B ). Both IL6 and IL8 were confirmed to be NF-kB targets in these cells as knockdown of RelA completely abolished their expression ( Figure 6B ). Thus, these results validated that both EZH2 and ER negatively regulate NF-kB target expression in ER-positive MCF7 and T47D cells.
EZH2 has been previously shown to interact with ER in MCF-7 cells (Shi et al., 2007) . Indeed, EZH2 and SUZ12 were detected in ER immunoprecipitates, indicating an interaction of PRC2 with ER ( Figure 6C ). Conversely, ER was detected in EZH2 immunoprecipitates. In both immunoprecipitates, RelA and RelB were not found. This indicates that PRC2 formed a complex with ER but not with RelA/RelB in MCF-7 cells. Notably, the PRC2-ER interaction was disrupted in TNFa-treated cells, suggesting a possibility that ER may recruit PRC2 to NF-kB target promoters for gene repression. Thus, disruption of PRC2-ER interaction upon TNFa treatment may result in reduced recruitment of the repressor complex to NF-kB target promoters, leading to their transactivation.
To verify this hypothesis, we performed ChIP analysis in MCF-7 cells. We detected marked enrichment of EZH2 and ER on IL6 and IL8 promoters, which are concomitant with high levels of H3K27me3 but low levels of RelA binding ( Figure 6D ). This observation is consistent with the silenced expression of IL6 
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FoxA1 GATA3 and IL8 by ER and EZH2 in MCF-7 cells, Moreover, after TNFa treatment over time, the amount of EZH2 and ER as well as H3K27me3 associated with IL6 and IL8 promoters dropped markedly, but RelA recruitment was increased ( Figure 6E ), corresponding to a strong induction of IL6 and IL8 ( Figure 6B ). These ChIP results were specific to IL6 and IL8 promoters as no difference was observed on the chromatin recruitment of these transcription factors to an adjacent site on IL6 or IL8 promoter ( Figure S4 ). These observations provide evidence that ER corecruitment of PRC2 to NF-kB target genes accounts for their silenced expression in MCF-7 cells. Lastly, ectopic RelB overexpression in MCF-7 cells results in strong induction of IL6, which was rescued by concomitant EZH2 knockdown. In contrast, RelB overexpression in MCF-7 cells only resulted in a modest induction of IL8 and concomitant EZH2 knockdown even further elevated its expression ( Figure 6F ). These results further demonstrate a crucial role of RelB in selective activation of NF-kB targets in a EZH2-dependent manner. IL8  IL6  BIRC3  IL11  IL24  CXCL1  CXCL2  FHOD3  SAA1  IL8  IL6  BIRC3  IL11  IL24  CXCL1  CXCL2  FHOD3 Based on the collective results of Figures 1-6 , we proposed a model for EZH2 regulation of NF-kB target gene expression in ER-positive and ER-negative breast cancer cells that is summarized in Figure 7 . In ER-negative breast cancer, overexpression of both EZH2 and RelB forms a complex with RelA to confer constitutive activation of NF-kB target gene expression. On the other hand, in ER-positive breast cancer cells where RelB expression is repressed, ER recruits PRC2 to NF-kB target gene promoters and function as a canonical epigenetic repressor. The differential expression of ER and RelB in the two contexts may be crucial for switching the role for EZH2 in regulating NF-kB target gene expression. Based on this model, we highlighted that EZH2 could play opposing roles in regulating NF-kB network through distinct mechanisms in a contextspecific dependent manner.
DISCUSSION
Our study identified a role for EZH2 in regulating NF-kB-dependent transcription in breast cancer. Intriguingly, we showed that EZH2 can function in both canonical and noncanonical manners to repress or activate NF-kB target gene expression, in a context-dependent manner. EZH2 confers a transactivation function on a set of NF-kB targets such as IL6 and TNF that are important in basal-like breast cancer but acts oppositely to repress NF-kB targets in ER-positive breast cancers. These findings identify EZH2 as a crucial modulator of NF-kB signaling that is known to be constitutively activated in ER-negative and basallike breast cancers (Van Laere et al., 2006) and suggest that the two important oncogenic signaling pathways may be coordinately involved in aggressive breast cancers. Significantly, we showed that EZH2 achieves this positive regulation on NF-kB targets without requiring its methyltransferase activity, which has advanced our understanding of EZH2 functions as an oncogene. In accordance with our finding is an earlier report that EZH2 could serve as an adaptor that links estrogen receptor and b-catenin to enhance their transcriptional activity (Shi et al., 2007) . Therefore, EZH2 may contribute to tumorigenesis through both positive and negative regulation of gene activity. Mechanistically, we show that EZH2 promotes NF-kB binding to a set of target gene promoters through direct physical interaction with RelA and RelB in basal-like breast cancer cells. In particular, RelB is shown to play a crucial role in this regulation. Although the noncanonical NF-kB pathway mediated by RelB has been generally considered to be different from RelA-mediated canonical pathway and governs distinct categories of target gene expression in nonmalignant models. In this study, we clearly see a significant set of NF-kB targets genes coregulated by both RelA and RelB in basal breast cancer cells. This indicates an oncogenic role of RelB in coregulating RelA targets in some malignance, which is consistent with a recent report that inhibition of RelB in prostate cancer can attenuate the canonical NF-kB target gene expression, resulting in decreased tumorigenicity (Xu et al., 2009) . Moreover, as shown previously and also in this study, constitutively activated RelB is associated with ERnegative basal-like breast cancers and promote their metastasis . Our data provide a molecular basis that links EZH2 and RelB in promoting NF-kB-mediated transcription in aggressive breast cancer. Importantly, the EZH2/RelB coregulated NF-kB targets we identified in MDA-MB-231 cells are highly associated with basal breast cancer cells and are predictive of poor prognosis of breast cancer patients. Considering the increasing importance of inflammatory cytokines such as IL6 and IL8 in contributing to breast cancer progression and selfrenewal of breast cancer stem cells (Iliopoulos et al., 2009 (Iliopoulos et al., , 2011 Liu and Wicha, 2010; Schafer and Brugge, 2007) , identification of EZH2-mediated regulation of autocrine inflammatory network mediated by NF-kB is important to understand the complicated gene network in aggressive breast cancers.
Intriguingly, EZH2 functions oppositely in ER-positive breast cancer cells. We have previously shown that EZH2 could negatively regulate inflammatory gene network in ER-positive and noninvasive breast cancer MCF7 cells ). This discrepancy may arise from the heterogeneous molecular profiles embedded in the two subtypes of breast cancers, in particular the ER status. It is a long known fact that ER is inhibitory to both RelB and NF-kB signaling in breast cancers and NF-kB targets are significantly elevated in ER-negative breast tumors (Freund et al., 2003; Gamba et al., 2010; Gionet et al., 2009; Kalaitzidis and Gilmore, 2005) , though the mechanism underlying this inhibition might not be necessary through inhibiting NF-kB's DNA binding capacity (Liu et al., 2005; Ray et al., 1997) . Consistent with this notion, we show in this study that ER recruits PRC2 to enforce a repressive chromatin modification at NF-kB target genes, thus providing an alternative mechanism to silence NF-kB target gene expression. In this scenario, ER-EZH2 occupancy at NF-kB target gene promoters is mutually exclusive with the occupancy of RelA. Upon TNFa induction of NF-kB targets, ER-PRC2 repressor complex as well as H3K27me3 mark was reduced concomitant with increased RelA association with NF-kB targets. TNFa treatment is known to increase RelA association with histone acetylase CBP/p300 at the target promoters (Gerritsen et al., 1997; Perkins et al., 1997) . Thus, the increased histone acetylation may confer a more open chromatin architecture that is not favorable for PRC2 recruitment upon TNFa treatment. Therefore, the counterbalance between ER and RelB expression in ER-positive and ER-negative basal breast cancer cells appears to be crucial for EZH2 to function as a repressor or activator in breast cancer cells.
Extrapolation of the findings in this study suggests a need for development of a context-specific strategy for therapeutic targeting of EZH2 in breast cancer. Our data suggest that therapeutic inhibition of EZH2 could be beneficial in basal-like breast cancers by attenuating the constitutive activation of NF-kB signaling, while targeting EZH2 in nonbasal breast cancers should be considered with caution. However, since this EZH2 function does not require its histone methyltransferase activity, an alternative strategy other than small molecular inhibition of EZH2 enzymatic activity needs to be developed. In this regard, approaches based on perturbation of the interaction between EZH2 and RelA/RelB might be appropriate.
EXPERIMENTAL PROCEDURES
Dual Luciferase Reporter Assays NF-kB-specific reporter plasmid pGL4.32 and its negative control pGL4.15 were purchased from Promega. Cells were harvested 48 hr after transfection and analyzed with the Dual Luciferase system (Promega).
Microarray Gene Expression Analyses and Quantitative RT-PCR Assays
Total RNA was isolated and microarray data analysis was performed as described (Wu et al., 2010) . Quantitative PCR assays were performed with the KAPA SyBr Fast qPCR kit (KAPA Biosystems). Primer sequences are listed in Supplemental Experimental Procedures.
Coimmunoprecipitation CoIP was performed as described previously (Jiang et al., 2008) . 293T and MDA-MB-231 nuclear lysate were extracted with the NE-PER kit (Pierce Biotechnology) , and 50 mg nuclear lysate was subjected to immunoprecipitation. See the Supplemental Experimental Procedures for details of the antibodies used.
Chromatin Immunoprecipitation and re-ChIP Assays ChIP assays were performed as described previously (Jiang et al., 2008) . Re-ChIP was performed as previously described (Tan et al., 2011) . See the Supplemental Experimental Procedures for details of the antibodies used and primer sequences.
Data Set and Survival Analysis
The breast cancer data set from Netherlands cohort with relevant clinical information has been described previously (Bos et al., 2009) . The EZH2/RelA/RelB coregulated gene subset was used to classify breast cancer patients into higher expression or lower expression groups based on the mean of the expression of the subset of genes. Using the survival event status and time information, we computed the survival association of expression status (high/low expression) using Cox-Proportional Hazards model implementation (coxph) available in R-library ''survival.'' Kaplan-Meier survival analysis was used for the analysis of clinical outcome.
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